European Archives - Page 636 of 1230 - European Medical Journal

Resilience After Rejection

Rejection is always painful, but it is particularly agonising to have a drug rejected at the point of regulatory approval. After spending months researching, preparing, manufacturing and quality checking a drug, only to be sent back to the drawing board, how can companies get back into their creationary swing straight away?

UTIs: Prevalent Yet Overlooked?

Scientists led a focus group study of 29 females experiencing recurrent UTIs in order to gain insight into the gaps in their care…

The Microbiome: The Answer to Reducing Prostate Cancer Risk?

This breaking research suggests that alterations in diet and lifestyle choices may be able to decrease risks of prostate cancer development…

Getting Down to Business

We speak with Andy Sleet, Managing Partner, OYF Ltd, who tells the story of how his career was turned on its head, steering him into business coaching.

EMJ Gastroenterology 10 [Supplement 2] 2021

Several clinicians informed attendees of UEG Week Virtual 2021 of their latest treatment-related insights and recommendations for gastroenterological diseases.

Updates in the Treatment of Gastroenterological Disorders

The United European Gastroenterology (UEG) Week Virtual 2021 illuminated a wide range of new insights and recommendations for…

The value of purpose

The corporate environment is evolving, and ‘purpose’ is more important than ever to young recruits looking for their next role. We examine how the pharmaceutical industry is embracing the importance of purpose for retention, reputation, and brand differentiation

Sustainable solutions for a greener tomorrow

From drug development to disposal, how can all processes and functions be considered through a greener lens, and work towards a healthier and safer future?

IS mRNA the future of vaccine technology?

The mRNA COVID-19 vaccine took only a year to develop – beating the previous fastest traditional vaccine development, held by the 1967 mumps vaccine, of four years. How does it differ from traditional vaccine technology?

Tamika Jean Baptiste

Tamika Jean-Baptiste on diversity and inclusion

Tamika Jean-Baptiste, Vice President and Chief Diversity Officer, Amgen, discusses her lifelong passion for diversity.